Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib, Bendamustine, and Rituximab in Previously Untreated Waldenstrom's Macroglobulinemia
NCT04624906Phase 2Active, not recruiting
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Mar 2021
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1) in Waldenstrom macroglobulinemia (WM), sponsored by Sunnybrook Health Sciences Centre. Started Mar 2021; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT04624906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04624906.